grant
Inflammatory caspase activation in sickle cell disease
Organization BAYLOR COLLEGE OF MEDICINELocation HOUSTON, UNITED STATESPosted 1 Apr 2024Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY20260-11 years old5 year old5 years of ageAllelesAllelomorphsApicalApoplexyApoptosis-Related Cysteine Protease Caspase 1Apoptosis-Related Cysteine Protease Caspase 5Apoptosis-Related Gene Caspase 5AsystoleBeta Proprotein Interleukin 1BindingBinding SitesBiologyBloodBlood PlasmaBlood Reticuloendothelial SystemBlood erythrocyteBody TissuesBrain DeadBrain DeathBrain Vascular AccidentCASP-1CASP1CASP1 geneCASP11CASP4CASP4 geneCASP5CASP5 ProteinCASP5 geneCRISPR approachCRISPR based approachCRISPR methodCRISPR methodologyCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 technologyCardiac ArrestCaringCas nuclease technologyCaspaseCaspase GeneCaspase-1Caspase-1 GeneCaspase-5 GeneCatalytic CoreCatalytic DomainCatalytic RegionCatalytic SiteCatalytic SubunitCell BodyCell DeathCell-Death ProteaseCell-Free SystemCellfree SystemCellsCerebral StrokeCerebrovascular ApoplexyCerebrovascular StrokeChildChild YouthChildren (0-21)Children's HospitalChronicClinicalClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyCodeCoding SystemComa DepasseCombining SiteCysteine EndopeptidasesCysteine ProteaseCysteine ProteinasesDataDiseaseDisorderDrugsEndothelial CellsErythrocytesErythrocyticEventFDA approvedFerroprotoporphyrinGene ExpressionGeneHomologHb SS diseaseHbSS diseaseHeartHeart ArrestHemeHemoglobin S DiseaseHemoglobin sickle cell diseaseHemoglobin sickle cell disorderHemolysisHomologHomologous GeneHomologueHumanICE ProteaseICE and CED3 Homolog 2ICE(rel)-IIIICE(rel)-III GeneICE-like proteaseICH-2ICH-3 ProteaseICH-3 Protease GeneICH3IL-1 betaIL-1 beta ConvertaseIL-1 beta-Converting EnzymeIL-1 βIL-1-bIL-1BCIL-1b Converting EnzymeIL-1βIL1-BetaIL1-βIL1B ProteinIL1B-ConvertaseIL1BCIL1BCEIL1F2IL1βIn VitroIndividualInflammasomeInflammationInflammatoryInflammatory ResponseInnate Immune ResponseInterdisciplinary ResearchInterdisciplinary StudyInterleukin 1-B Converting EnzymeInterleukin 1-Beta ConvertaseInterleukin 1betaInterleukin-1 Beta Converting EnzymeInterleukin-1 Converting EnzymeInterleukin-1 betaInterleukin-1βInterruptionInvestigationKnock-outKnockoutKnowledgeLifeLife ExpectancyLungLung Respiratory SystemMOF syndromeMacrophageMarrow erythrocyteMeasuresMediatorMedicationMiceMice MammalsMissionModelingModern ManMolecular InteractionMouse Homolog of Caspase 11Multidisciplinary CollaborationMultidisciplinary ResearchMultiple Organ Dysfunction SyndromeMultiple Organ FailureMurineMusMφNHLBINational Heart, Lung, and Blood InstituteNecrosisNecroticOrganOutcomePainPainfulPathway interactionsPatientsPediatric HospitalsPersonsPharmaceutical PreparationsPhysiologicPhysiologicalPlasmaPlasma SerumPreinterleukin 1 BetaProtohemePublic HealthReactive SiteRed Blood CellsRed CellReportingResearchReticuloendothelial System, Serum, PlasmaRoleSamplingSickle Cell AnemiaStrokeStructural ModelsSymptomsTY ProteaseTY Protease GeneTestingTexasTissuesVDAC1VDAC1 geneVariantVariationacute chest syndromeage 5age 5 yearsblood corpusclesbrain attackcaspase-5cerebral deathcerebral vascular accidentcerebrovascular accidentchronic painchronic symptomcohortcomputer based predictioncystein proteasecystein proteinasecysteine endopeptidasecytokinedimerdisease phenotypedrug/agenterythrolysisexperimentexperimental researchexperimental studyexperimentsextracellularferrohemefive year oldfive years of agegene delivery systemimproved outcomeindividual patientinhibitorinjury to organsinsightkidslow income countrymonomermultiorgan failuremultiple organ system failurenecrocytosisnew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetorgan injurypathwaypersistent symptompore forming proteinporinpredictive modelingpreventpreventingprotein complexrecruitresponsescaffoldscaffoldingsickle cell diseasesickle cell disordersickle diseasesicklemiasicklingsocial rolestrokedstrokessystemic inflammationsystemic inflammatory responsevaso-occlusive crisisvasoocclusive crisisyoungster
Description preview
SUMMARY
New, inexpensive, accessible treatments are urgently needed to regulate chronic inflammation in sickle cell dis-
ease (SCD). SCD is a devastating red blood cell disorder that impacts millions of people worldwide. The majority
of clinical symptoms in SCD, including stroke, vaso-occclusive crisis (VOC), and acute chest syndrome (ACS)
are…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click